Rethinking HIV prevention to prepare for oral PrEP implementation for young African women

Introduction HIV incidence remains high among young women in sub‐Saharan Africa in spite of scale‐up of HIV testing, behavioural interventions, antiretroviral treatment and medical male circumcision. There is a critical need to critique past approaches and learn about the most effective implementation of evidence‐based HIV prevention strategies, particularly emerging interventions such as pre‐exposure prophylaxis (PrEP). Discussion Women in sub‐Saharan Africa are at increased risk of HIV during adolescence and into their 20s, in part due to contextual factors including gender norms and relationship dynamics, and limited access to reproductive and sexual health services. We reviewed behavioural, behavioural economic and biomedical approaches to HIV prevention for young African women, with a particular focus on the barriers, opportunities and implications for implementing PrEP in this group. Behavioural interventions have had limited impact in part due to not effectively addressing the context, broader sexual norms and expectations, and structural factors that increase risk and vulnerability. Of biomedical HIV prevention strategies that have been tested, daily oral PrEP has the greatest evidence for protection, although adherence was low in two placebo‐controlled trials in young African women. Given high efficacy and effectiveness in other populations, demonstration projects of open‐label PrEP in young African women are needed to determine the most effective delivery models and whether women at substantial risk are motivated and able to use oral PrEP with sufficient adherence to achieve HIV prevention benefits. Conclusions Social marketing, adherence support and behavioural economic interventions should be evaluated as part of PrEP demonstration projects among young African women in terms of their effectiveness in increasing demand and optimizing uptake and effective use of PrEP. Lessons learned through evaluations of implementation strategies for delivering oral PrEP, a first‐generation biomedical HIV prevention product, will inform development of new and less user‐dependent PrEP formulations and delivery of an expanding choice of prevention options in HIV prevention programmes for young African women.